Predicting response to biologics for severe asthma through breath analysis

Severe eosinophilic asthma can now be treated with biologic therapies that reduce attacks and, in some cases, allow corticosteroid dose reductions. However, not all patients respond to these treatments, and it remains difficult to predict in advance who will benefit from them. A study conducted by scientists at the University of Liège and Liège University Hospital proposes using a "simple" breath sample to guide treatment selection even before it begins. The findings are published in the American Journal of Respiratory and Critical Care Medicine.

≈